Research summary
Snap-8
A synthetic SNAP-25 mimetic octapeptide that inhibits catecholamine release at the neuromuscular junction, studied for expression line reduction.
Dermal PeptideSynthetic neuropeptide (SNAP-25 mimetic)AAs8MW1,073.2 g/molCAS868844-74-0Safety8/10NCAANot listed
Evidence at a glance
What the research says about Snap-8
The Snap-8 evidence base cited here is 4 sources — 2 clinical, 1 review. Its strongest evidence is human — 2 clinical studies, most recently 2025 ("Acetyl Hexapeptide-8 in Cosmeceuticals — Skin Permeability and Efficacy"). Regulatory status: Cosmetic use (topical).
Key findings
What the literature shows
- Octapeptide (Acetyl Octapeptide-3 / SNAP-8) that competitively inhibits the SNARE complex formation, reducing neurotransmitter release at the neuromuscular junction — a topical botulinum toxin-alternative mechanism.
- Clinical data from Lipotec reported a ~63% reduction in wrinkle depth on the forehead after 28 days in a double-blind vehicle-controlled study.
- 2025 IJMS study confirmed skin permeability at effective concentrations and demonstrated anti-wrinkle efficacy comparable to acetyl hexapeptide-3 variants.
Citations
4 peer-reviewed sources
All citations link to the original source (PubMed, journal site, or regulatory filing). Independent research database — no vendor influence on what's cited.
Clinical2 sources
Database1 source
Related research